<!doctype html><html lang=tw><head><meta charset=utf-8><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><meta name=referrer content="no-referrer"><link rel=dns-prefetch href=https://i.geekbank.cf/><title>指南速遞 | 2019 ACOG實踐簡報：女性性功能障礙（No.213）（上） | 极客快訊</title><meta property="og:title" content="指南速遞 | 2019 ACOG實踐簡報：女性性功能障礙（No.213）（上） - 极客快訊"><meta property="og:type" content="article"><meta property="og:locale" content="tw"><meta property="og:image" content="https://p3.pstatp.com/large/pgc-image/23b99b468575493a94091b4c6c7516ec"><link rel=alternate hreflang=x-default href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/9a0f1cfd.html><link rel=alternate hreflang=zh-tw href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/9a0f1cfd.html><link rel=alternate hreflang=zh-cn href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%b8/9a0f1cfd.html><link rel=alternate hreflang=zh-hk href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/9a0f1cfd.html><link rel=alternate hreflang=zh-mo href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/9a0f1cfd.html><link rel=alternate hreflang=zh-my href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%b8/9a0f1cfd.html><link rel=alternate hreflang=zh-sg href=https://geekbank.cf/cn/%e7%a7%91%e5%ad%b8/9a0f1cfd.html><link rel=canonical href=https://geekbank.cf/tw/%e7%a7%91%e5%ad%b8/9a0f1cfd.html><meta property="article:published_time" content="2020-11-14T20:58:37+08:00"><meta property="article:modified_time" content="2020-11-14T20:58:37+08:00"><meta name=Keywords content><meta name=description content="指南速遞 | 2019 ACOG實踐簡報：女性性功能障礙（No.213）（上）"><meta name=author content="极客快訊"><meta property="og:url" content="/tw/%E7%A7%91%E5%AD%B8/9a0f1cfd.html"><link rel=apple-touch-icon sizes=180x180 href=../../apple-touch-icon.png><link rel=icon type=image/png sizes=32x32 href=../../favicon-32x32.png><link rel=icon type=image/png sizes=16x16 href=../../favicon-16x16.png><link rel=manifest href=../../site.webmanifest><link rel=mask-icon href=../../safari-pinned-tab.svg color=#5bbad5><meta name=msapplication-TileColor content="#ffc40d"><meta name=theme-color content="#ffffff"><link rel=stylesheet href=https://geekbank.cf/css/normalize.css><link rel=stylesheet href=https://geekbank.cf/css/style.css><script type=text/javascript src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js></script><script type=text/javascript src=https://geekbank.cf/js/jqthumb.min.js></script><script data-ad-client=ca-pub-3525055026201463 async src=https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js></script></head><body><header id=header class=clearfix><div class=container><div class=col-group><div class=site-name><h1><a id=logo href>🤓 极客快訊 Geek Bank</a></h1><p class=description>為你帶來最全的科技知識 🧡</p></div><div><nav id=nav-menu class=clearfix><a class=current href>猜你喜歡</a>
<a href=../../tw/categories/%E7%A7%91%E6%8A%80.html title=科技>科技</a>
<a href=../../tw/categories/%E9%81%8A%E6%88%B2.html title=遊戲>遊戲</a>
<a href=../../tw/categories/%E7%A7%91%E5%AD%B8.html title=科學>科學</a></nav></div></div></div></header><div id=body><div class=container><div class=col-group><div class=col-8 id=main><div class=res-cons><article class=post><header><h1 class=post-title>指南速遞 | 2019 ACOG實踐簡報：女性性功能障礙（No.213）（上）</h1></header><date class="post-meta meta-date">2020-11-14</date><div class=post-meta><span>|</span>
<span class=meta-category><a href=tw/categories/%E7%A7%91%E5%AD%B8.html>科學</a></span></div><div class=post-content><div><p>譯者：譚曉偉 煙臺毓璜頂醫院</p><p>審校：徐暉 山東大學第二醫院</p><div class=pgc-img><img alt="指南速遞 | 2019 ACOG實踐簡報：女性性功能障礙（No.213）（上）" onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/23b99b468575493a94091b4c6c7516ec><p class=pgc-img-caption></p></div><p>女性性功能障礙</p><p>女性性功能障礙的情況是多方面的，主要是對以下一種或多種方面感到痛苦：性慾望、性衝動、性高潮或性交疼痛(1)。儘管女性性功能障礙的問題相對比較普遍，但是女性不太可能與他們的衛生保健提供者主動討論這個問題,除非被刻意問到(2)，許多衛生保健提供者因為種種原因也不願意問這個問題，比如其對性功能障礙患者的診斷與管理缺乏足夠的知識和培訓，處理問題的臨床時間不充足 ，低估了性功能障礙的普遍性。本文的目的是對女性性功能障礙進行綜述，概述最新的診斷標準，並根據現有的有效證據討論目前推薦的管理策略。</p><p>背景</p><p>大約有43%的美國婦女曾報告自己在性方面存在問題，有12%的人因性功能障礙導致的個人痛苦而感到很煩惱 (3)。女性性功能障礙的發病率從中年階段開始增加，在18至44歲年齡段的女性當中大約有10%存在性困擾， 45至64歲年齡段的女性存在性困擾問題的比例達到15% 的峰值，然後在老年階段又下降，在65至85歲年齡段的老年女性中，性功能障礙的發病率下降到9%左右(3)。表框1列出了一些更常見的性功能障礙的病因和危險因素。</p><p>正常性反應</p><p>對於女性正常性反應的最初研究傾向於線性模型(4-6)。而更現代女性性反應模型是非線性的，包括女性性反應原始四個階段以及其他階段的各種序列 (圖1)(7)。今天，我們把中樞神經內分泌系統通過調整性興奮和性抑制因素之間平衡來調節女性性反應的過程描述為動態的過程 (8)。</p><p>雌激素在女性性生理(包括維持生殖器官組織的敏感性、彈性、分泌物、pH值和微生物菌群)、排尿節律、盆底肌張力和關節活動方面起著關鍵作用(8,12)。外周血雌激素隨著女性的衰老自然減少，也會因手術或藥物所致雌激素減少導致更年期的到來，雌激素的這些變化會對女性性功能產生多種多樣的影響(7,12)。</p><p>女性的雄激素水平在20多歲時達到頂峰，在育齡期早期(直到30多歲)急劇下降，在60歲左右趨於穩定，自60歲以後不再進一步的下降(13-15)。睪酮在調節女性性慾和性功能方面的作用尚不清楚。雖然有證據表明短期應用經皮吸收睪酮藥物對性慾低下的絕經後婦女有益，但是並沒有特定的雄激素或雄激素前體血清水平或下限值可作為女性性功能減退的診斷標準(16-18)。</p><p>性功能障礙的類型</p><p>美國精神病學協會的《精神障礙診斷與統計學手冊(第五版)》(DSM-5)確定了四種特定類型的女性性功能障礙(1)(表框1)。此外，DSM-5還將性功能障礙分為“其他特定性功能障礙”和“非特定性功能障礙”。</p><div class=pgc-img><img alt="指南速遞 | 2019 ACOG實踐簡報：女性性功能障礙（No.213）（上）" onerror=errorimg.call(this); src=https://p1.pstatp.com/large/pgc-image/10f840477fa04985904559448ac6f8c8><p class=pgc-img-caption></p></div><p>女性性慾和覺醒障礙</p><p>女性性慾覺醒障礙是一種新的分類，它取代了DSM-IV術語中的性慾減退和女性性覺醒障礙。(在本文件中，性慾減退僅用於描述使用DSM-IV-TR標準考量的一種條件或結果的研究。)性慾和性喚起的波動可能會伴隨女性一生，這些波動由一些個人的 或性伴侶因素引起，但是常常會被忽略。這些因素包括睡眠模式的改變或長期睡眠質量下降，壓力，身體外貌、身材或體重的變化，妊娠，哺乳，久坐不動的生活方式，酗酒或其他藥物濫用，人際關係因素等(19-26)。許多女性說她們缺乏性慾望或性衝動，意味著她們已經失去了對性的生理渴望。她們描述了性的問題，但是他們考慮的是如何避免性行為，或者是如何通過性行為來維持一段感情或者是通過性來滿足其伴侶的需求 (27)。女性還描述了一種痛苦，就是她們雖然對性沒有興趣，但是當其性伴侶開始有性活動時，她們也能被喚醒 (27)。</p><p>雖然女性的性興趣和性喚起障礙問題可以在沒有診斷出的併發病的情況下發生，但新的併發病可能是未被診斷或亞臨床條件下的一個指標，甚至在年輕女性群體中也是如此(28)。藥物治療，特別是選擇性血清素再攝取抑制劑(SSRIs)，通常與性喚起相關(框1)(29)。</p><div class=pgc-img><img alt="指南速遞 | 2019 ACOG實踐簡報：女性性功能障礙（No.213）（上）" onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/fb929134d5854a8ab0f5c52b072ea4cd><p class=pgc-img-caption></p></div><p>期待慾望、生理喚醒、主觀喚醒、性喚醒及慾望響應、回報（身體或心理滿足）、性動機、主觀自願、性刺激及環境、大腦處理信息。</p><p>框1所示。女性的性反應。循環的性反應週期呈現出重疊的變階式階段。性動機有很多，性慾可能在一開始就存在，也可能不存在，但在大腦將性信號處理為性喚醒(與性慾合併)之後便產生了性動機。後者進一步增強性衝動，允許接受逐漸強烈的性刺激。</p><p>(Basson R. Sexuality and sexual disorders. Clin Update Womens Health Care 2014;XIII(2);1–108. Available at:https://www.clinicalupdates.org/viewissue.cfm?</p><p>issue5cuwhc-v13n2. Retrieved February 22,2019.)</p><div class=pgc-img><img alt="指南速遞 | 2019 ACOG實踐簡報：女性性功能障礙（No.213）（上）" onerror=errorimg.call(this); src=https://p9.pstatp.com/large/pgc-image/b98f10b52a304a97b754c35b170a38f8><p class=pgc-img-caption></p></div><p>*當女性存在性功能障礙時，只要排除無性的精神疾病、性伴侶痛苦關係（比如性伴侶暴力）、化學物質、藥物及其他醫學治療引起的性功能障礙就可診斷為性功能障礙疾病。</p><p>性功能障礙無法用一種獨立的性功能障礙疾病來詮釋。有證據表明，非化學物質/藥物引起的性功能障礙，應包括有獨立的性功能障礙病史，在應用化學物質或藥物治療前就存在症狀，在急性戒斷或嚴重中毒終止後症狀至少持續一個月。</p><p>Data from American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): APA;2013.</p><p>女性性高潮障礙</p><p>女性性高潮障礙的定義為明顯的性高潮時間延遲、性高潮稀發、無性高潮或明顯的高潮快感強度降低(1)。原發性性高潮障礙的女性通常有正常的性慾水平(27)。大多數性高潮障礙患者是獲得性的，與新開始的醫學治療、解剖學異常、伴侶關係不和諧、個人行為改變、以及心理狀況相關 (表框1)，通常表現為性慾及性覺醒障礙、生殖器盆腔痛及陰道插入障礙症狀並存 (1)。在個別罕見案例當中，獲得性高潮障礙可能是由潛在神經系統疾病、生殖器或盆底手術相關損傷、放療或藥物治療引起 (1 7)。儘管研究資料非常有限,但是接受過生殖器官切除手術的女性可能有終生性高潮障礙或獲得性性高潮障礙，且她們患性功能障礙的風險更高(30)。</p><p>生殖器盆腔痛和陰道插入障礙</p><p>陰道痙攣和性交困難現在已併入生殖器-盆腔疼痛和陰道插入障礙。這種障礙可能是終生的，也可能是後天獲得性的。生殖器-盆腔疼痛和陰道插入障礙包括以下一種或多種症狀：陰道肌肉緊縮，接受插入的能力降低或根本無法接受陰莖插入；性伴侶嘗試插入陰道時女性會感到緊張、疼痛或灼燒感；性交的慾望減少或沒有性交慾望；逃避性行為；對疼痛的強烈恐懼與害怕 (1)。生殖器-盆腔疼痛和陰道插入障礙的症狀常常同時出現，多是由重疊的醫學、環境和心理社會原因一起導致的，解除這些病因後，疼痛或陰道插入障礙症狀便可得到緩解 (31,32)。需要注意的是，即便患者的性行為不包括性交，只要她們存在性功能相關疼痛，那麼她們仍然可能患有這種疾病。</p><p>化學物質或藥物因素所致性功能障礙</p><p>化學物質或藥物引起的性功能障礙是臨床上一種重要的性功能障礙，多發生於服用某種藥物時，或服藥後不久，或停服某種藥物時。這些化學物質或藥物很容易被認為有引起性功能障礙的作用 (1)。與其他類型的女性性功能障礙相比,這種性功能障礙的診斷要求病人有相關的痛苦經歷。抗膽鹼能藥物、激素藥物、心血管病藥物和精神病藥物可能與女性性功能障礙有關(24)。酒精、大麻和麻醉劑也可能導致女性性功能障礙。</p><p>其他特定或非特定性功能障礙</p><p>病人表現出性功能障礙的痛苦症狀，但是又不符合已經定義的性功能障礙的分類標準，這種性功能障礙可以診斷為其他特定或非特定性功能障礙 (1)。其他特定性功能障礙和其他非特定性功能障礙之間主要區別是臨床醫生確定引起患者所描述症狀的病因不符合其他性功能障礙分類標準。</p><p>妊娠相關性功能障礙</p><p>任何類型的孕期性功能障礙都是產後性功能障礙的一個關鍵風險因素。剖宮產、器械助產、會陰切開術和會陰撕裂引起的創傷也會增加發生產後生殖器-盆腔痛和陰道插入障礙疾病的風險，並與性慾和性覺醒功能障礙存在相關性 (33-36)。母乳餵養還會導致陰道乾燥，從而出現生殖器-盆腔疼痛/陰道插入障礙的症狀。女性產後面臨許多問題，比如長期睡眠紊亂，母親角色改變，家庭關係問題，新生兒健康問題，親子關係社會心理調整(對女性和她的伴侶)，產後身體改變。這些女性產後問題與產科分娩相關因素相比，產科因素似乎是產後女性性功能障礙更重要的驅動因素 (35)。產後抑鬱症除了與性慾減退和性生活頻率降低有關外(37)，還可能有潛在的嚴重健康風險，需要早發現並及時干預 (38)。家庭暴力在懷孕期間可能升級，對婦女及其新生兒的整體健康和幸福構成嚴重威脅，並與產後性功能障礙有關(39)。產後女性性功能障礙的評估和管理類似於非產後女性性功能障礙的評估、管理和治療，只是進行了一些修改，以避免應用哺乳期禁用的醫學治療。</p><p>更年期相關性功能障礙</p><p>2014年，根據美國女性性健康與北美更年期協會的研究，國際學會提出絕經後泌尿生殖系統綜合徵的術語，這一術語不但描繪了陰道萎縮，同時還包含了全部生殖系統改變、性功能障礙症狀及泌尿系統症狀，這些症狀均與更年期發生的外周血雌激素及其他類固醇激素水平下降有關 (12)。典型症狀包括令人煩惱的陰道乾澀、灼燒和刺激感；性交時陰道潤滑性降低及性交疼痛；尿急、排尿困難和複發性尿路感染 (12)。據估計，高達50%的更年期婦女受到更年期泌尿生殖系統綜合徵相關症狀的影響(40,41)，在育齡期，更年期泌尿生殖系統綜合徵也可能發生，比如低雌激素狀態(如產後)或使用芳香化酶抑制劑等抗激素藥物期間(42,43)。</p><p>臨床思考與建議</p><p><strong>如何進行女性性功能障礙篩查？</strong></p><p>婦產科醫生應在日常對病人進行診療與隨訪期間就開始對性功能進行臨床討論，以確定可能需要進一步探討的問題，並幫助消除患者對討論性功能問題的偏見(44-46)。在患者入院時讓其填寫簡短的性功能自查表，例如使用患者報告的結果測量信息系統研究框架（47）開發的經過驗證的單項選擇題，可能有助於促進對性功能的臨床討論。在日常衛生保健訪談中介紹性功能的另一種方法是使用一種寬泛的陳述模式，目的是使問題正常化，然後是一個封閉式問題和一個開放式問題(48)。例如，“許多女性都經歷過對性的擔憂，你在性方面有什麼問題嗎(是/否)? 你在擔心什麼?”提出這個話題的另一種方式是在日常的聚會中提出寬泛的、開放式的問題。如果發現了性方面的問題，建議進行後續評估。</p><p><strong>對於可能存在性功能障礙的婦女，我們應該如何初步處理？</strong></p><p>對女性性功能障礙患者的初步評估可能需要較長時間的隨訪，並應包括綜合病史採集(45、46、49、51)和體格檢查，以評估可能的婦科病因。在最初評估女性性功能障礙時，通常不需要實驗室檢測，除非懷疑有未診斷的醫學病因。</p><p>全面的病史採集</p><p>詳細的性生活史應包括病人的性生活和性別認同問題；性功能障礙症狀的性質、持續時間和發病時間；個人對症狀有怎樣的苦惱；自我保健情況、自我用藥情況或其他接受過哪些減輕症狀的治療；性伴侶因素，包括目前的性伴侶數量以及他們的性生活情況、身體健康問題和性功能問題；與性伴侶的關係是否融洽，包括病人的性問題；既往和現在所遭受的虐待或暴力(44,52)；可能影響生殖器-盆腔部位的個人體力勞動、損傷(如跨騎傷或尾骨傷)和生活習慣(如個人衛生和久坐)；睡眠質量；個人身體變化或形象問題(如乳房切除術、造瘻術後或妊娠)(49,51)。同樣，糟糕的伴侶關係和伴侶性功能障礙也應該得到認知和解決。由於一種性功能障礙可能引發另一種性問題 (例如，疼痛可能導致性慾喪失)，應評估現症情況以及症狀未來的發展情況。瞭解處方藥和非處方藥物和化學物質的使用情況。在科研領域，我們已經有了各種有效的自我報告問卷來評估有性功能障礙症狀女性的性功能，這些問卷也可能用來幫助進行臨床訪談和性生活史採集 (53)。例如女性性功能指數(54)和女性性困擾量表(55)。</p><p>體格檢查</p><p>一般來說，婦科檢查的重點是在病史採集時已經確定的重點部位，可以幫助我們評估可能導致或促成性功能障礙的原發性婦科疾病 (56)。正在接受女性性功能障礙檢查的婦女可能會受益於有機會在鏡子的幫助下查看和參與檢查。對其進行簡短的生殖器官教育,包括觀看生殖器官插圖，識別陰蒂，陰脣，尿道，陰道口，陰道前廳。可以幫助病人更好的告訴醫生疼痛的位置以及其他性功能障礙症狀的情況。也可以幫助衛生保健提供者更好的跟病人溝通體格檢查結果並提出治療建議。有一種描繪疼痛症狀的方法是使用棉籤系統地輕觸前庭來定位不適區域(57)，儘管這項測試的特異性受到了人們的質疑(58)。</p><p>診斷</p><p>性功能障礙症狀持續至少6個月(除外化學物質/藥物引起的性功能障礙)，並且給病人造成明顯的個人痛苦，診斷為DSM-5女性性功能障礙(表1)。此外，診斷需排除非性心理健康障礙、醫療狀況、嚴重的人際關係困擾或其他重大的生活壓力，以及化學物質或藥物影響 (除外化學物質/藥物引起的性功能障礙)。我們必須要記住，女性經常經歷不止一種類型的性功能障礙。即使女性的性功能症狀不符合DSM-5標準，她仍然可以從性功能評估和治療中獲益。</p><p>心理干預在女性性功能障礙治療中的作用是什麼？</p><p>作為女性性功能障礙治療的一部分，我們建議進行心理干預，包括性技巧訓練、行為認知治療(包括藥物治療或非藥物治療)、基於心智覺知的治療和夫妻治療。應綜合考慮婦產科醫生的專業水平和患者的個人治療意願，向具有治療女性性功能障礙方面的專業知識並接受過培訓的精神衛生專家(如性治療師、心理學家、精神病學家和婚姻/情感關係顧問)諮詢或推介。</p><p>性技能訓練，如手淫指導，長期以來一直是治療性高潮障礙的主要方法(59)。一些有高潮障礙的患者確實通過手淫或其他性刺激體驗到了性高潮，但他們並不認為這些體驗就是高潮。在其他案例當中，女性缺乏關於陰蒂刺激的知識或經驗，以及認為陰蒂刺激是不被允許的或者對手淫感到內疚和羞愧，都是引發性功能障礙的原因 (60)。通過加強與性伴侶進行性需求和性偏好的溝通,進行感覺集中練習，和系統脫敏療法(61)以及加強教育和行為技術訓練，改變女性消極態度和減輕焦慮情緒，來增加女性身體舒適度和性慾望(60)。遭受過性侵犯的女性性高潮障礙患者可能會受益於創傷心理治療 (62)。基於小組的或基於夫妻的認知行為療法專注於識別和改變功能失調信念，可能有助於改善性慾低下 (61，63-65)。心智覺知療法，是隻專注於體驗當下，不加判斷地接受自己的想法和感受，已被證明有助於改善幾種不同類型的女性性功能障礙，包括性慾/覺醒障礙和獲得性高潮缺乏症(61,66)。</p><p><strong>專家簡介</strong></p><div class=pgc-img><img alt="指南速遞 | 2019 ACOG實踐簡報：女性性功能障礙（No.213）（上）" onerror=errorimg.call(this); src=https://p3.pstatp.com/large/pgc-image/b19755408d9c492089dc0763d15a8226><p class=pgc-img-caption></p></div><p>徐暉</p><p>徐暉，男，1973年3月出生。1997年6月畢業於山東醫科大學臨床醫學系，獲得學士學位，2010年6月畢業於山東大學醫學院，獲得婦產科碩士學位。自1997年7月至今在在山東大學第二醫院婦產科從事臨床醫療工作。2013年9月聘為副主任醫師。主要擅長婦科腫瘤、微創領域。承擔山東省科技廳及衛計委基金項目各一項，迄今在國內外雜誌發表論文7篇，SCI收錄2篇, 主編專著2部，參編專著7部。</p><p>主要社會兼職</p><p>1.山東中西醫結合學會生殖內分泌專業委員會常務委員</p><p>2.山東省微量元素科學研究會婦產科專業委員會第一屆委員</p><p>3.山東省抗癌協會婦科腫瘤分會首屆青年委員會委員</p><p>4.山東省醫師協會婦科微創醫師分會第一屆委員會委員</p><p>5. 山東省醫師協會婦產科醫師分會子宮內膜異位症和慢性盆腔痛委員會第一屆委員</p><p>6. 濟南市健康服務促進會常務理事</p><p>參考文獻</p><p>1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): APA; 2013. (Level III)</p><p>2. Kingsberg SA. Taking a sexual history. Obstet Gynecol Clin North Am 2006;33:535–47. (Level III)</p><p>3. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:970–8. (Level II-3)</p><p>4. Kinsey AC. Sexual behavior in the human female. Philadelphia (PA): Saunders; 1953. (Level III)</p><p>5. Masters WH, Johnson VE. Human sexual response. Boston (MA): Little, Brown and Company; 1966. (Level III)</p><p>6. Kaplan HS. Disorders of sexual desire and other new concepts and techniques in sex therapy. New York (NY): Simon and Schuster; 1979. (Level III)</p><p>7. Basson R. Sexuality and sexual disorders. Clin Update Womens Health Care 2014;XIII(2):1–108. (Level III)</p><p>8. Archer JS, Love-Geffen TE, Herbst-Damm KL, Swinney DA, Chang JR. Effect of estradiol versus estradiol and testosterone on brain-activation patterns in postmenopausal women. Menopause 2006;13:528–37. (Level III)</p><p>9. Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects of female sexual dysfunction. J Sex Med 2004;1: 82–6. (Level III)</p><p>10. Kingsberg SA, Clayton AH, Pfaus JG. The female sexual response: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder. CNS Drugs 2015;29:915–33. (Level III)</p><p>11. Salonia A, Giraldi A, Chivers ML, Georgiadis JR, Levin R, Maravilla KR, et al. Physiology of women’s sexual function: basic knowledge and new findings. J Sex Med 2010;7:2637–60. (Level III)</p><p>12. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Menopause 2014;21:1063–8. (Level III)</p><p>13. Burger HG, Papalia MA. A clinical update on female androgen insufficiency—testosterone testing and treatment in women presenting with low sexual desire. Sex Health 2006;3:73–8. (Level III)</p><p>14. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005;90:3847–53. (Level II-3)</p><p>15. Kingsberg SA. The impact of aging on sexual function in women and their partners. Arch Sex Behav 2002;31:431– 7. (Level III)</p><p>16. Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, et al. Correlates of circulating androgens in mid-life women: the study of women’s health across the nation. J Clin Endocrinol Metab 2005; 90:4836–45. (Level II-3)</p><p>17. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91–6. (Level II-3)</p><p>18. Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3489–510. (Systematic Review)</p><p>19. Abdool Z, Thakar R, Sultan AH. Postpartum female sexual function. Eur J Obstet Gynecol Reprod Biol 2009;145: 133–7. (Level III)</p><p>20. Cabral PU, Canario AC, Spyrides MH, Uchoa SA, Eleuterio J Jr, Goncalves AK. Determinants of sexual dysfunction among middle-aged women. Int J Gynaecol Obstet 2013;120:271–4. (Level II-3)</p><p>21. Dean J, Rubio-Aurioles E, McCabe M, Eardley I, Speakman M, Buvat J, et al. Integrating partners into erectile dysfunction treatment: improving the sexual experience for the couple. Int J Clin Pract 2008;62:127–33. (Level III)</p><p>22. Galazka I, Drosdzol-Cop A, Naworska B, Czajkowska M, Skrzypulec-Plinta V. Changes in the sexual function during pregnancy. J Sex Med 2015;12:445–54. (Level II-2)</p><p>23. Kalmbach DA, Arnedt JT, Pillai V, Ciesla JA. The impact of sleep on female sexual response and behavior: a pilot study. J Sex Med 2015;12:1221–32. (Level II-2)</p><p>24. McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, et al. Risk factors for sexual dysfunction among women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 2016;13:153–67. (Level III)</p><p>25. Ter Kuile MM, Vigeveno D, Laan E. Preliminary evidence that acute and chronic daily psychological stress affect sexual arousal in sexually functional women. Behav Res Ther 2007;45:2078–89. (Level I) 26. Wiederman MW. Women’s body image selfconsciousness during physical intimacy with a partner. J Sex Res 2000;37:60–8. (Level II-3)</p><p>27. Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K, et al. Revised definitions of women’s sexual dysfunction. J Sex Med 2004;1:40–8. (Level III)</p><p>28. Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med 2009;6: 1549–60. (Level II-2)</p><p>29. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol 2009;29:259–66. (Meta-analysis)</p><p>30. Berg RC, Underland V, Odgaard-Jensen J, Fretheim A, Vist GE. Effects of female genital cutting on physical health outcomes: a systematic review and meta-analysis. BMJ Open 2014;4:e006316. (Systematic Review and Meta-analysis)</p><p>31. Basson R. Female sexual response: the role of drugs in the management of sexual dysfunction [published erratum appears in Obstet Gynecol 2001;98:522]. Obstet Gynecol 2001;98:350–3. (Level III) 32. Steege JF, Zolnoun DA. Evaluation and treatment of dyspareunia. Obstet Gynecol 2009;113:1124–36. (Level III)</p><p>33. Macleod M, Goyder K, Howarth L, Bahl R, Strachan B, Murphy DJ. Morbidity experienced by women before and after operative vaginal delivery: prospective cohort study nested within a two-centre randomised controlled trial of restrictive versus routine use of episiotomy. BJOG 2013; 120:1020–6. (Level I)</p><p>34. McDonald E, Woolhouse H, Brown SJ. Consultation about sexual health issues in the year after childbirth: a cohort study. Birth 2015;42:354–61. (Level II-2)</p><p>35. McDonald EA, Gartland D, Small R, Brown SJ. Dyspareunia and childbirth: a prospective cohort study. BJOG 2015;122:672–9. (Level II-2)</p><p>36. Signorello LB, Harlow BL, Chekos AK, Repke JT. Postpartum sexual functioning and its relationship to perineal trauma: a retrospective cohort study of primiparous women. Am J Obstet Gynecol 2001;184:881–8; discussion 888–90. (Level II-2)</p><p>37. DeJudicibus MA, McCabe MP. Psychological factors and the sexuality of pregnant and postpartum women. J Sex Res 2002;39:94–103. (Level II-3)</p><p>38. Screening for perinatal depression. ACOG Committee Opinion No. 757. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;132:e208–12. (Level III)</p><p>39. Intimate partner violence. Committee Opinion No. 518. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;119:412–7. (Level III)</p><p>40. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133–42. (Level II-3)</p><p>41. Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric 2012;15:36–44. (Level II-3)</p><p>42. Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc 2017;92:1842–9. (Level III)</p><p>43. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888-902; quiz 903–4. (Level III)</p><p>44. Sexual health. Committee Opinion No. 706. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e42–7. (Level III)</p><p>45. Simon JA, Lukas VA. Distressing sexual function at midlife: unmet needs, practical diagnoses, and available treatments. Obstet Gynecol 2017;130:889–905. (Level III)</p><p>46. Kingsberg S. Just ask! Talking to patients about sexual function. Sex Reprod Menopause 2004;2:199–203. (Level III)</p><p>47. Flynn KE, Lindau ST, Lin L, Reese JB, Jeffery DD, Carter J, et al. Development and validation of a singleitem screener for self-reporting sexual problems in U.S. adults. J Gen Intern Med 2015;30:1468–75. (Level II-2)</p><p>48. Parish SJ, Hahn SR. Hypoactive sexual desire disorder: a review of epidemiology, biopsychology, diagnosis, and treatment. Sex Med Rev 2016;4:103–20. (Level III)</p><p>49. Althof SE, Rosen RC, Perelman MA, Rubio-Aurioles E. Standard operating procedures for taking a sexual history. J Sex Med 2013;10:26–35. (Level III)</p><p>50. Hatzichristou D, Rosen RC, Derogatis LR, Low WY, Meuleman EJ, Sadovsky R, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010;7:337–48. (Level III)</p><p>51. Nusbaum MR, Hamilton CD. The proactive sexual health history. Am Fam Physician 2002;66:1705–12. (Level III)</p><p>52. Reproductive and sexual coercion. Committee Opinion No. 554. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;121:411–5. (Level III)</p><p>53. Latif EZ, Diamond MP. Arriving at the diagnosis of female sexual dysfunction. Fertil Steril 2013;100:898– 904. (Level III)</p><p>54. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208. (Level 111)</p><p>55. Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002;28:317–30. (Level III)</p><p>56. Lindau ST, Abramsohn EM, Baron SR, Florendo J, Haefner HK, Jhingran A, et al. Physical examination of the female cancer patient with sexual concerns: What oncologists and patients should expect from consultation with a specialist. CA Cancer J Clin 2016;66:241–63. (Level III)</p><p>57. Witzeman K, Nguyen RH, Eanes A, As-Sanie S, Zolnoun D. Mucosal versus muscle pain sensitivity in provoked vestibulodynia. J Pain Res 2015;8:549–55. (Level II-2)</p><p>58. Vieira-Baptista P, Lima-Silva J, Beires J, Donders G. Women without vulvodynia can have a positive “Q-tip test”: a cross sectional study. J Psychosom Obstet Gynaecol 2017;38:256–9. (Level II-3)</p><p>59. Heiman JR, Meston CM. Empirically validated treatment for sexual dysfunction. Annu Rev Sex Res 1997;8:148– 94. (Level III)</p><p>60. Meston CM, Levin RJ, Sipski ML, Hull EM, Heiman JR. Women’s orgasm. Annu Rev Sex Res 2004;15:173–257. (Level III)</p><p>61. Brotto L, Atallah S, Johnson-Agbakwu C, Rosenbaum T, Abdo C, Byers ES, et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J Sex Med 2016;13:538–71. (Systematic Review)</p><p>62. Zoldbrod AP. Sexual issues in treating trauma survivors. Curr Sex Health Rep 2015;7:3–11. (Level III) 63. Fruhauf S, Gerger H, Schmidt HM, Munder T, Barth J. Efficacy of psychological interventions for sexual dysfunction: a systematic review and meta-analysis. Arch Sex Behav 2013;42:915–33. (Systematic Review)</p><p>64. Faubion SS, Rullo JE. Sexual dysfunction in women: a practical approach [published erratum appears in Am Fam Physician 2016;94:189]. Am Fam Physician 2015; 92:281–8. (Level III)</p><p>65. Gunzler C, Berner MM. Efficacy of psychosocial interventions in men and women with sexual dysfunctions— a systematic review of controlled clinical trials: part 2— the efficacy of psychosocial interventions for female sexual dysfunction. J Sex Med 2012;9:3108–25. (Systematic Review)</p><p>66. Brotto LA, Basson R, Luria M. A mindfulness-based group psychoeducational intervention targeting sexual arousal disorder in women. J Sex Med 2008;5:1646–59. (Level II-3)</p><p>67. Lindau ST, Dude A, Gavrilova N, Hoffmann JN, Schumm LP, McClintock MK. Prevalence and correlates of vaginal estrogenization in postmenopausal women in the United States. Menopause 2017;24:536–45. (Level II-2)</p><p>68. Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews 2016, Issue 8. Art. No.: CD001500. DOI: 10.1002/14651858.CD001500. pub3. (Systematic Review)</p><p>69. Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med 2018;178:681–90. (Level I)</p><p>70. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2015;18:121–34. (Level III)</p><p>71. Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Society of Gynecologic Surgeons Systematic Review Group. Obstet Gynecol 2014;124:1147–56. (Systematic Review)</p><p>72. Management of menopausal symptoms. Practice Bulletin No. 141. American College of Obstetricians and Gynecologists [published erratum appears in Obstet Gynecol 2016;127:166]. Obstet Gynecol 2014;123:202–16. (Level III)</p><p>73. The 2017 hormone therapy position statement of The North American Menopause Society. The</p><p>NAMS 2017Hormone Therapy Position Statement Advisory Panel. Menopause 2017;24:728–53. (Level III)</p><p>74. Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med 2014;11: 487–97. (Systematic Review)</p><p>75. Portman D, Palacios S, Nappi RE, Mueck AO. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial. Maturitas 2014;78:91– 8. (Level I)</p><p>76. Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause 2015;22:36–43. (Level II-1)</p><p>77. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Committee Opinion No. 659. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;127:e93–6. (Level III)</p><p>78. Management of gynecologic issues in women with breast cancer. Practice Bulletin No. 126. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012; 119:666–82. (Level III)</p><p>79. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002;99:556–62. (Level I)</p><p>80. Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril 2017;107:475–82.e15. (Systematic Review and Meta-analysis)</p><p>81. Shifren JL, Gass ML. The North American Menopause Society recommendations for clinical care of midlife women. NAMS Recommendations for Clinical Care of Midlife Women Working Group. Menopause 2014;21: 1038–62. (Level III)</p><p>82. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005;165: 1582–9. (Level I)</p><p>83. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944–52. (Level I)</p><p>84. Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial [published erratum appears in Menopause 2006;13:850]. Menopause 2006;13:387–96. (Level I)</p><p>85. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study [published erratum appears in Menopause 2007;14:157]. Menopause 2006;13:770–9. (Level I)</p><p>86. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90:5226–33. (Level I)</p><p>87. Davis S, Papalia MA, Norman RJ, O’Neill S, Redelman M, Williamson M, et al. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med 2008;148:569–77. (Level I)</p><p>88. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 2003;10:390–8. (Level II-3)</p><p>89. Hakim C, Padmanabhan V, Vyas AK. Gestational hyperandrogenism in developmental programming. Endocrinology 2017;158:199–212. (Level III)</p><p>90. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. APHRODITE Study Team. N Engl J Med 2008;359:2005–17. (Level I)</p><p>91. Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 2010;13:121–31. (Level I)</p><p>92. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas 2008;61:17–26. (Level I)</p><p>93. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol 2011;27:39–48. (Level I)</p><p>94. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil Steril 2003;79:1341– 52. (Level I)</p><p>95. Sherwin BB. Use of combined estrogen-androgen preparations in the postmenopause: evidence from clinical studies. Int J Fertil Womens Med 1998;43:98–103. (Level III)</p><p>96. Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2012;9: 1134–48. (Level III)</p><p>97. Urman B, Pride SM, Yuen BH. Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 1991;77:595–8. (Level III) 98. Ness RB, Albano JD, McTiernan A, Cauley JA. Influence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med 2009;169:41–6. (Level II-2)</p><p>99. Elraiyah T, Sonbol MB, Wang Z, Khairalseed T, Asi N, Undavalli C, et al. Clinical review: the benefits and harms of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.</p><p>100. Panjari M, Bell RJ, Jane F, Wolfe R, Adams J, Morrow C, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med 2009;6:2579–90. (Level I)</p><p>101. Scheffers CS, Armstrong S, Cantineau AE, Farquhar C, Jordan V. Dehydroepiandrosterone for women in the perior postmenopausal phase. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD011066. DOI: 10.1002/14651858.CD011066.pub2. (Systematic Review and Meta-analysis) 102. Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med 2016;176:453–62. (Systematic Review and Metaanalysis)</p><p>103. Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause 2014;21: 633–40. (Level I)</p><p>104. ADDY (flibanserin) tablets 100 mg. Raleigh (NC): Sprout Pharmaceuticals, Inc; 2018. Available at: https:// addyi.com/assets/pdf/Addyi_full_prescribing_info.pdf. Retrieved February 26, 2019. (Level III)</p><p>105. Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomised controlled trial. BJOG 2003;110:1014–24. (Level I)</p><p>106. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;11: 367–77. (Level I)</p><p>107. Berman JR, Berman LA, Toler SM, Gill J, Haughie S. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. Sildenafil Study Group. J Urol 2003; 170:2333–8. (Level I)</p><p>108. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebocontrolled study. BJOG 2001;108:623–8. (Level II-3)</p><p>109. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 2008;300:395–404. (Level I)</p><p>110. Taylor MJ, Rudkin L, Bullemor‐Day P, Lubin J, Chukwujekwu C, Hawton K. Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD003382. DOI: 10.1002/14651858. CD003382.pub3.(Systematic Review and Meta-analysis)</p><p>111. Safarinejad MR. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. J Psychopharmacol 2011;25:370–8. (Level I)</p><p>112. Wilson SK, Delk JR 2nd, Billups KL. Treating symptoms of female sexual arousal disorder with the Eros-Clitoral Therapy Device. J Gend Specif Med 2001;4:54–8. (Level III)</p><p>113. Billups KL. The role of mechanical devices in treating female sexual dysfunction and enhancing the female sexual response. World J Urol 2002;20:137–41. (Level III)</p><p>114. Guess MK, Connell KA, Chudnoff S, Adekoya O, Richmond C, Nixon KE, et al. The effects of a genital vibratory stimulation device on sexual function and genital sensation. Female Pelvic Med Reconstr Surg 2017;23: 256–62. (Level II-2)</p><p>115. Persistent vulvar pain. Committee Opinion No. 673. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;128:e78–84. (Level III)</p><p>116. Paquet M, Rosen NO, Steben M, Mayrand MH, SanterreBaillargeon M, Bergeron S. Daily anxiety and depressive symptoms in couples coping with vulvodynia: associations with women’s pain, women’s sexual function, and both partners’ sexual distress. J Pain 2018;19:552–61. (Level II-3)</p><p>117. Melles RJ, Dewitte MD, Ter Kuile MM, Peters MM, de Jong PJ. Attentional bias for pain and sex, and automatic appraisals of sexual penetration: differential patterns in dyspareunia vs vaginismus? J Sex Med 2016;13:1255– 62. (Level II-1)</p><p>118. Leo RJ, Dewani S. A systematic review of the utility of antidepressant pharmacotherapy in the treatment of vulvodynia pain. J Sex Med 2013;10:2497–505. (Systematic Review)</p><p>119. Melnik T, Hawton K, McGuire H. Interventions for vaginismus. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD001760. DOI: 10.1002/14651858. CD001760.pub2. (Systematic Review)</p><p>120. Reissing ED, Armstrong HL, Allen C. Pelvic floor physical therapy for lifelong vaginismus: a retrospective chart review and interview study. J Sex Marital Ther 2013;39: 306–20. (Level III)</p><p>121. Ter Kuile MM, Melles R, de Groot HE, TuijnmanRaasveld CC, van Lankveld JJDM. Therapist-aided exposure for women with lifelong vaginismus: a randomized waiting-list control trial of efficacy. J Consult Clin Psychol 2013;81:1127–36. (Level I)</p><p>122. Haefner HK, Collins ME, Davis GD, Edwards L, Foster DC, Hartmann ED, et al. The vulvodynia guideline. J Low Genit Tract Dis 2005;9:40–51. (Level III)</p><p>123. Polpeta NC, Giraldo PC, Teatin Juliato CR, Gomes Do Amaral RL, Moreno Linhares I, Romero Leal Passos M. Clinical and therapeutic aspects of vulvodynia: the importance of physical therapy. Minerva Ginecol 2012;64:437– 45. (Level III)</p><p>124. Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia</p><p>125. Crisp CC, Vaccaro CM, Estanol MV, Oakley SH, Kleeman SD, Fellner AN, et al. Intra-vaginal diazepam for high-tone pelvic floor dysfunction: a randomized placebo-controlled trial. Int Urogynecol J 2013;24: 1915–23. (Level I)</p><p>126. Leo RJ. A systematic review of the utility of anticonvulsant pharmacotherapy in the treatment of vulvodynia pain. J Sex Med 2013;10:2000–8. (Systematic Review)</p><p>127. Foster DC, Kotok MB, Huang LS, Watts A, Oakes D, Howard FM, et al. Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. Obstet Gynecol 2010;116:583–93. (Level I)</p><p>128. Reed SD, Mitchell CM, Joffe H, Cohen L, Shifren JL, Newton KM, et al. Sexual function in women on estradiol or venlafaxine for hot flushes: a randomized controlled trial. Obstet Gynecol 2014;124:233–41. (Level I)</p><p>129. Nesbitt-Hawes EM, Won H, Jarvis SK, Lyons SD, Vancaillie TG, Abbott JA. Improvement in pelvic pain with botulinum toxin type A—single vs. repeat injections. Toxicon 2013;63:83–7. (Level I)</p><p>130. Lara LA, Useche B, Ferriani RA, Reis RM, de Sa MF, de Freitas MM, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response. J Sex Med 2009;6:30–9. (Level III)</p><p>131. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94. (Level III)</p><p>132. Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. J Sex Med 2016;13:305– 16. (Level III)</p><p>133. Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med 2013;10:1575–84. (Level I)</p><p>134. Juraskova I, Jarvis S, Mok K, Peate M, Meiser B, Cheah BC, et al. The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. J Sex Med 2013;10:2549–58. (Level II-2)</p><p>135. Sokol ER, Karram MM. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause 2016;23:1102–7. (Level III)</p><p>136. Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014;17:363–9. (Level III)</p><p>137. American College of Obstetricians and Gynecologists. Fractional laser treatment of vulvovaginal atrophy and U.S. Food and Drug Administration clearance. Position Statement. Washington, DC: ACOG; 2016. Available at: https://www.acog.org/Clinical-Guidance-and-Publications/ Position-Statements/Fractional-Laser-Treatment-of-VulvovaginalAtrophy-and-US-Food-and-Drug-Administration-Clearance. Retrieved February 13, 2019. (Level III) e</p></div></div><div class="post-meta meta-tags"><ul class=clearfix><li><a>速遞</a></li><li><a>2019</a></li><li><a>ACOG</a></li></ul></div></article></div></div><div id=secondary><section class=widget><form id=search action=//www.google.com/search method=get accept-charset=utf-8 target=_blank _lpchecked=1><input type=text name=q maxlength=20 placeholder=搜索>
<input type=hidden name=sitesearch value=geekbank.cf>
<button type=submit>🔍</button></form></section><section class=widget><h3 class=widget-title>最新文章 ⚡</h3><ul class=widget-list><li><a href=../../tw/%E7%A7%91%E5%AD%B8/a07625e.html alt=信息速遞｜2018~2019學年第一學期第六週講座預告 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/pgc-image/R6ljQv4CUd9zWS style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E5%AD%B8/a07625e.html title=信息速遞｜2018~2019學年第一學期第六週講座預告>信息速遞｜2018~2019學年第一學期第六週講座預告</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/21d2ba3e.html alt=2019年土木畢業生要知道的那些事 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/21d2ba3e.html title=2019年土木畢業生要知道的那些事>2019年土木畢業生要知道的那些事</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/171b22b4.html alt=2019年度《特種鑄造及有色合金》優秀論文結果公佈 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p9.pstatp.com/large/137c70000b816835d80bf style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/171b22b4.html title=2019年度《特種鑄造及有色合金》優秀論文結果公佈>2019年度《特種鑄造及有色合金》優秀論文結果公佈</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/817e1015.html alt=2019年度《特種鑄造及有色合金》網絡評選結果出爐 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p9.pstatp.com/large/pgc-image/66c26cbe459a4361b1d501e4bbac6c88 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/817e1015.html title=2019年度《特種鑄造及有色合金》網絡評選結果出爐>2019年度《特種鑄造及有色合金》網絡評選結果出爐</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/df18bcc1.html alt=金川集團公司2019年全國合金鑄造行業商洽會舉行 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/df18bcc1.html title=金川集團公司2019年全國合金鑄造行業商洽會舉行>金川集團公司2019年全國合金鑄造行業商洽會舉行</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/3c5292d6.html alt="2019年度數字孿生城市之無人機 航攝應用及真三維建模技術培訓班" class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/3c5292d6.html title="2019年度數字孿生城市之無人機 航攝應用及真三維建模技術培訓班">2019年度數字孿生城市之無人機 航攝應用及真三維建模技術培訓班</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/fcd2a59f.html alt=2019年最爆笑的120個名場面合集 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/pgc-image/dc6fcd05f35e499a9ef7a2d19ff9c66b style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/fcd2a59f.html title=2019年最爆笑的120個名場面合集>2019年最爆笑的120個名場面合集</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/715eacc1.html alt=《獅子王》2019：引入VR虛擬製作技術，顛覆動畫電影拍攝 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/pgc-image/9a08cc2f25cb41c5be515de0d79879a9 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/715eacc1.html title=《獅子王》2019：引入VR虛擬製作技術，顛覆動畫電影拍攝>《獅子王》2019：引入VR虛擬製作技術，顛覆動畫電影拍攝</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/e342e11c.html alt="2019掌上生活10元風暴怎麼玩攻略 快速獲取小招喵方法" class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/pgc-image/Rk8ZSn39iz0Be8 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/e342e11c.html title="2019掌上生活10元風暴怎麼玩攻略 快速獲取小招喵方法">2019掌上生活10元風暴怎麼玩攻略 快速獲取小招喵方法</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/67fef4c6.html alt=2019年高考，怎樣設置院校梯度才合理？衝、穩、保、墊，很關鍵！ class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p3.pstatp.com/large/dfic-imagehandler/f8d17716-f3b8-4c6d-8eb7-f482334ad491 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/67fef4c6.html title=2019年高考，怎樣設置院校梯度才合理？衝、穩、保、墊，很關鍵！>2019年高考，怎樣設置院校梯度才合理？衝、穩、保、墊，很關鍵！</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/e18c5b5e.html alt=2019年正在流行的16個網頁設計趨勢 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/pgc-image/RPgQdSQEjBTN6Z style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/e18c5b5e.html title=2019年正在流行的16個網頁設計趨勢>2019年正在流行的16個網頁設計趨勢</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/d72ed228.html alt=2019年中式烹調師（技師）安全生產模擬考試題庫及答案（一） class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/pgc-image/fbcf9bc4d8224c309106305ad34adf9a style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/d72ed228.html title=2019年中式烹調師（技師）安全生產模擬考試題庫及答案（一）>2019年中式烹調師（技師）安全生產模擬考試題庫及答案（一）</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/d4044e1f.html alt=2019年中式烹調師（高級）安全生產模擬考試題庫及答案（一） class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/d4044e1f.html title=2019年中式烹調師（高級）安全生產模擬考試題庫及答案（一）>2019年中式烹調師（高級）安全生產模擬考試題庫及答案（一）</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/f855d5ae.html alt=2019年中式烹調師（高級）安全生產模擬考試題庫及答案（二） class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/pgc-image/9796cfd44f754f9ab22310d91088423e style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/f855d5ae.html title=2019年中式烹調師（高級）安全生產模擬考試題庫及答案（二）>2019年中式烹調師（高級）安全生產模擬考試題庫及答案（二）</a></li><hr><li><a href=../../tw/%E7%A7%91%E6%8A%80/9adee5f1.html alt=2019中式烹調師（技師）在線免費模擬考試系統及模擬題庫2 class="image featured" style=display:block;margin-left:auto;margin-right:auto;width:100%><img src=https://p1.pstatp.com/large/pgc-image/d6a75905fb9346ccb6e4c8a304a79e63 style=border-radius:25px></a>
<a href=../../tw/%E7%A7%91%E6%8A%80/9adee5f1.html title=2019中式烹調師（技師）在線免費模擬考試系統及模擬題庫2>2019中式烹調師（技師）在線免費模擬考試系統及模擬題庫2</a></li><hr></ul></section><section class=widget><h3 class=widget-title>其他</h3><ul class=widget-list><li><a href=TOS.html>使用條款</a></li><li><a href=CommentPolicy.html>留言政策</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>DMCA</a></li><li><a href=mailto:gdnews@tuta.io rel=nofollow>聯絡我們</a></li></ul></section></div></div></div></div><footer id=footer><div class=container>&copy; 2020 <a href>极客快訊</a></div></footer><script type=text/javascript>window.MathJax={tex2jax:{inlineMath:[['$','$']],processEscapes:true}};</script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML" async></script><a id=rocket href=#top></a><script type=text/javascript src=https://kknews.cf/js/totop.js async></script><script type=text/javascript src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-5e508ed9e4e698bb"></script></body></html>